Screening for Cancer in Patients with Glomerular Diseases

Emmanuelle Plaisier; Pierre Ronco

doi:10.2215/CJN.09000819

Screening for Cancer in Patients with Glomerular Diseases

Clin J Am Soc Nephrol. 2020 Jun 8;15(6):886-888. doi: 10.2215/CJN.09000819. Epub 2020 Feb 4.

Authors

Emmanuelle Plaisier^{1

2

3

4

5}, Pierre Ronco^{1

2

3

4

5}

Affiliations

¹ Department of Nephrology Day Hospital, Tenon Hospital Assistance Publique des Hôpitaux de Paris, Paris, France.
² Research Unit UMRS 1155, National Institute of Heath and Medical Research-INSERM, Paris, France.
³ Sorbonne Université, Paris 06, Paris, France.
⁴ Reference Center of Rare disease- idiopathic Nephrotic Syndrome, Paris, France.
⁵ European Rare Kidney Disease Reference Network-ERKNet, Heidelberg, Germany.

No abstract available

Keywords: Cancer; cost-benefit analysis; cytosolic phospholipases A2; early detection of cancer; follow-up studies; human PLA2R1 protein; humans; immunosuppressive agents; kidney; membranoproliferative glomerulonephritis; membranous nephropathy; neoplasms; nephrologists; nephrology; nephrotic syndrome; phospholipase A2 receptors; phospholipases A2; recurrence; risk factors; thrombospondins; treatment failure.

MeSH terms

Autoantibodies / metabolism
Early Detection of Cancer*
Glomerulonephritis, Membranous / etiology*
Glomerulonephritis, Membranous / metabolism
Humans
Neoplasms / complications
Neoplasms / diagnosis*
Nephrotic Syndrome / etiology*
Nephrotic Syndrome / pathology
Nephrotic Syndrome / therapy*
Paraneoplastic Syndromes / complications
Receptors, Phospholipase A2 / immunology
Risk Factors
Thrombospondins / immunology

Substances

Autoantibodies
PLA2R1 protein, human
Receptors, Phospholipase A2
THSD7A protein, human
Thrombospondins